89bio Balance Sheet Health
Financial Health criteria checks 5/6
89bio has a total shareholder equity of $378.1M and total debt of $35.5M, which brings its debt-to-equity ratio to 9.4%. Its total assets and total liabilities are $458.3M and $80.2M respectively.
Key information
9.4%
Debt to equity ratio
US$35.54m
Debt
| Interest coverage ratio | n/a |
| Cash | US$423.77m |
| Equity | US$378.10m |
| Total liabilities | US$80.20m |
| Total assets | US$458.30m |
Recent financial health updates
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 26
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 07Recent updates
89bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 2689bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 0789bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 0789bio: Undervalued Contender In Race For First NASH Drug Approval
Jul 20We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 0789bio: NASH Drug Developer With Differentiated Profile
Jan 29Financial Position Analysis
Short Term Liabilities: ETNB's short term assets ($456.2M) exceed its short term liabilities ($39.1M).
Long Term Liabilities: ETNB's short term assets ($456.2M) exceed its long term liabilities ($41.1M).
Debt to Equity History and Analysis
Debt Level: ETNB has more cash than its total debt.
Reducing Debt: ETNB's debt to equity ratio has increased from 0% to 9.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ETNB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ETNB has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 38.5% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 03:48 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
89bio, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |